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it is a direct measure of treatment effect on tumour burden andmeasures only the
effect of the study drug. PFS has also been accepted by regulatory bodies as a
measure of the efficacy of cancer treatments. CONCLUSIONS: OS is generally re-
garded as the preferable endpoint (from a payer’s perspective) for demonstrating
clinical efficacy in NSCLC. There are challenges, however, with demonstrating OS
benefit of new therapies for NSCLC. PFS data may be more appropriate for use in
certain situations, especially those in which subsequent lines of therapy exist.
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OBJECTIVES: The objective of the study was to propose an alternative indirect
comparison method and compare it to the standard method. METHODS: In the
absence of head-to-head trials, the standard method for estimating indirect rela-
tive effectiveness is to obtain an indirect hazard ratio (HR) estimate using the two
HRs from the comparator trials against a common 3rd one. This method, however,
is only valid if the assumption of proportional hazard (PH) holds. We proposed an
alternative indirect comparison method that does not depend on the PH assump-
tion, which consists of calculating the absolute difference between treatment arms
at each two-week period in drug B trial and applying this difference to the common
comparator in drug A trial to generate the adjusted curve for drug B. This was done
for Progression free Survival (PFS) and Overall Survival (OS) from parametric esti-
mates throughout the observed and extrapolated periods. Trial data for cetuximab
and panitumumab in 1st line treatment of wild-type KRAS metastatic colorectal
cancerwas used to examine the PH assumption and compared the twomethods for
estimating the relative treatment effect between the two agents. RESULTS: The
functional form for the PFS and OS distributions was found to be different for
panitumumab versus cetuximab (Weibull shape parameter value for: PFS1.616
versus 1.761; OS1.314 versus 1.336, respectively). Thus, the PH assumption was
violated. Panitumumab trial was set as the reference (the estimated mean PFS
0.917 years and mean OS2.469). Using the standard method and our proposed
method, the indirectly estimated PFS and OS for cetuximab were: mean PFS 0.846
vs 0.920 years; mean OS 2.393 versus 2.312 years, respectively. CONCLUSIONS:
The standard methodology for indirect comparison allows easy execution. How-
ever, if the PH assumption is violated, alternative methods, such as the one pro-
posed in this study, can be considered.
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OBJECTIVES: The objective of this study was to develop a unique linked Medicare-
Medicaid-WV Cancer Registry (WVCR) de-identified dataset to determine health
care utilization, costs and overall burden of breast, colorectal, lung, and prostate
cancers diagnosed in persons  65 years of age who live in WV and to compare
themwith national estimates.METHODS: The data linkagewas performed in three
phases, following process as originally described by Potosky (1993) and adapted by
Bradley (2007) and Koroukian (2008). In phase one, a list of individual’s65 years of
age with incident diagnosis of any cancer between January 1, 2002 and December
31, 2007 was extracted from WVCR data. The SSN, Sex, and Date of Birth of these
individuals were sent to CMS to create a crosswalk file for these individuals to
include with purchased WV Medicare data. In phase two, Medicare data were
linked with WVCR data using the crosswalk file provided by CMS. In phase three,
WVCR data were linked with Medicaid enrollment file data using personal identi-
fiers. After the linkages, all identifiers were removed to create a de-identified re-
search data set. RESULTS: In phase one, we identified 42,288 individuals’65 years
of age with incident diagnosis of any cancer from 2002 to 2007 in the WVCR data.
When linked with Medicare data in the second phase, 41,575 (98.3 %) individuals
were matched. In phase three, WVCR data were matched with Medicaid enroll-
ment data for 5790 (13.7%) individuals using SSN, First Name, and Last Name; for
5860 (13.9%) individuals using SSN, Last Name, Month of Birth, and Sex; and, for
5747 (13.6%) individuals using SSN, First Name, Month of Birth, and Sex.
CONCLUSIONS: Non-participant states in SEER-Medicare can build a powerful
linked Medicare-Medicaid-Cancer Registry dataset to identify and target cancer
disparities to improve outcomes in their elderly and dual-eligible citizens.
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OBJECTIVES: Electronic medical records (EMRs) are used increasingly for research.
Our objectives were a) to understand the utility of an EMR oncology database com-
pared with SEER cancer registry data and Medicare and commercial claims data-
bases and b) to identify areas for improvement in data collection, analysis, and
interpretation in clinical oncology, epidemiology, and comparative effectiveness
research. METHODS: Demographic, clinical, and treatment characteristics in the
four databases were compared using six tumor types: breast, lung/bronchus, head/
neck, colorectum, prostate, and NHL. Data imputation was performed using the
hot-deckmethod; patient characteristics were compared using Cohen’s effect size.
We described patient and clinic inclusion criteria, treatment definitions, and pur-
poses of each database to enable comparisons. RESULTS: Sex and 10-year age
distributions for each tumor type were similar across datasets. The EMR oncology
database had a large proportion of missing data for stage (70%) and race (40%),
which were replaced with imputed values. There were several differences in racial
composition (15%) and ambulatory chemotherapy treatment (30%), andmodest
(10%), differences in distribution of tumor type likely due to differences in geo-
graphic distribution of included patients and clinics. Overall, Cohen’s effects size
analyses indicated small to medium differences (w0.3) in patient characteristics
across databases. Patients in the EMRdatabaseweremore likely to receive biologics
and less likely to receive hormones compared to those in the reference databases,
with the largest differences (40%) observed in prostate cancer patients, who are
usually seen first or primarily by urologists. CONCLUSIONS: Several factors must
be consideredwhen using EMRs for oncology research purposeswith a target of the
US cancer population, particularly when evaluating treatment patterns. Important
factors include evaluation of stage, geography, race, andmedical facilities’ special-
ization. EMR database utility might be enhanced through imputation, addition of
specific physician notes (e.g., stage) and linkage to other data sources.
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OBJECTIVES: To create an overview that makes researchers aware of the available
database linkages in Northern America and Europe which facilitate pharmacoepi-
demiologic studies in cancer patients.METHODS: In addition to our own database,
i.e. the Eindhoven Cancer Registry (ECR) linked to the PHARMO RLS, we considered
database linkages between a population-based cancer registry, that provides de-
tailed tumor information of incident cancer cases, and an administrative health-
care database, that at least contains information on drug use and offers a longitu-
dinal perspective on health care utilization before, during and after cancer
diagnosis. Eligible database linkages should have been used in multiple published
articles in English language included in Pubmed. The Cancer Research Network
(CRN) in the United States was excluded from this review, as an overview of the
linked databases participating in the CRN is already provided elsewhere. Research-
ers who hadworkedwith the data resources included in our reviewwere contacted
for additional information and verification of the data presented in the overview.
RESULTS: Ten database linkages met the inclusion criteria: the SEER-Medicare,
cancer registry data linked to Medicaid, the British Columbia Cancer Registry and
Health data, the Saskatchewan Health Plan Databases, the Scottish cancer registry
linked to the Tayside drug dispensing data, linked databases in the Nordic Coun-
tries of Europe: Norway, Sweden, Finland and Denmark, and the ECR-PHARMO
linkage in The Netherlands. Descriptives of included database linkages comprise
population size, generalizability of the population, year of first data availability,
vital status, contents of the cancer registry, contents of the administrative health-
care database, the possibility to select a cancer-free control cohort, and linkage to
other health care databases. CONCLUSIONS: Various valuable resources of infor-
mation are available to study the disease management of cancer, including treat-
ment patterns and outcomes assessments, creating new opportunities for post-
approval evaluation of anti-cancer drugs.
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OBJECTIVES: Cancer treatment models are often based on progression-free sur-
vival (PFS) and overall survival (OS) data. If the model objective requires extrapo-
lating results or exploring “what-if” scenarios, disease progression parameters are
calibrated so that the model replicates the PFS and OS data. Uncertainties in the
estimation of the Kaplan-Meier survival curves used as calibration targets, and in
the model calibration process itself, are not commonly incorporated into sensitiv-
ity analyses. The objective of this study was to demonstrate methods for incorpo-
rating these uncertainties into probabilistic sensitivity analyses (PSA) and to ex-
plore their implications. METHODS: We constructed hypothetical PFS and OS
survival (with censoring) for two treatments (TxA & TxB) and a corresponding
three-state Markov model (Non-progressed (NP), Progressed (P), Dead (D)). Health
states were assigned costs and utilities consistent with advanced cancer. Three
transition probabilities for each treatment (NP-P, NP-D, P-D) were calibrated
(using Excel Solver) to simultaneously fit (using mean squared deviation) the
PFS/OS curves. We performed three increasingly comprehensive PSAs using sec-
ond-order Monte Carlo simulation (SMCS): 1) conventional PSA including only
probability distributions of costs and utilities; 2) specifying beta distributions for
failure probabilities at each PFS/OS timepoint, simulatingmultiple replicates of the
PFS /OS data from these distributions, re-estimating and refitting the curves for
each replicate, and incorporating the resulting calibrated parameter sets into the
SMCS; and 3) incorporating different curve-fitting methods by varying Solver pa-
rameters (initial values, constraints, objective function). Uncertainty in cost-effec-
tiveness results was represented by cost-effectiveness acceptability curves (CEAC).
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RESULTS: At a threshold of $100,000/QALY, the CEAC for PSA1 showed a 97% prob-
ability that TxB is cost-effective versus TxA, corresponding results for PSA2, and
PSA3, were 54%, and 58%, respectively. CONCLUSIONS: Failure to consider uncer-
tainties owing to PFS/OS data in oncology models, and to the ensuing calibration
procedures, can lead to under-representation of uncertainty in cost-effectiveness
results.
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OBJECTIVES: Because bone metastases can cause costly SREs, lifetime estimates of
SREs prevented can help payers compare the effectiveness of treatment options. De-
nosumab was recently approved in the US for SRE prevention in patients with bone
metastases from solid tumors. This study presents amodel for SRE predictions based
on phase III trials comparing denosumab and ZA in different tumors. METHODS: A
three-state Markov model (On Treatment, Off Treatment, and Dead) was developed
using constant SRE incidence rates for each tumor type and treatment. Results were
comparedbetween themodeland trial for the3-year trial durationandextrapolated to
the patient lifetime. Lifetime SREs were estimated for the US population based on the
estimated annual number of newpatientswith bonemetastases.Mortality rateswere
identical between treatments and estimated using trial-based generalized gamma
distributions. Lifetime treatment was assumed. RESULTS: The number of all SREs
observed (rateper patient-year) for denosumabandZAwere 660 (0.488) and853 (0.631)
for breast cancer, 780 (0.746) and943 (0.947) for prostate cancer, and469 (0.588) and535
(0.690) for other solid tumors. Comparisonbetween trial results andmodel projections
over the trial time horizon resulted in differences in SRE counts ranging from -1.5% to
2.0%.Over the expectedpatient lifetime, estimatedSREsperpatientwere 1.80 and2.32
(denosumab and ZA) for breast cancer, 1.65 and 2.08 for prostate cancer, and 1.36 and
1.60 for other solid tumors. In annual incident cohorts of patients with bonemetasta-
ses, themodel projects 43,765 and 56,408 (denosumab and ZA) lifetime SREs in breast
cancer and 30,429 and 38,359 lifetime SREs in prostate cancer. CONCLUSIONS: The
model output is consistentwith the clinical trial evidence, and canbeused to compare
estimates of the predicted lifetime SREs for denosumab and ZA.
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OBJECTIVES:Accurate estimates of cancer epidemiology are fundamental to quan-
tifying the economic burden of cancer as well as supporting a variety of researches
in public health and commercial activities. However, the complete prevalence and
incidence of late-stage cancers is difficult to obtain as most surveillance programs
report cases at initial diagnosis, so recurrent cases, by definition are not captured.
The objective of this study is to present a simple mathematical approach to esti-
mate the epidemiology of late-stage cancers. METHODS: We developed an Excel-
based tool to estimate the epidemiology of late-stage cancerswithminimal historic
information. Data needed include annual national or local cancer-relatedmortality
rates, late-stage cancer survival rates and population size. Our approach starts
with the patients who died from the specific cancer and tracks back to estimate the
incidence and prevalence. The approach assumes most deaths attributed to the
cancer are late-stage disease. We tested our approach by estimating the incidence
and prevalence ofmetastatic breast cancer andmetastaticmelanomawith historic
mortality and survival data from the National Cancer Institute Surveillance, Epi-
demiology and End Results (SEER) Program. RESULTS:We estimated that the 2007
US incidence of stage IV breast cancer andmelanomawere approximately 32.4 per
100,000 women and 2.7 per 100,000 persons, respectively. These results corre-
sponded to a total of 49,505 patients (10,426 newly diagnosed and 39,079 recurrent
cases) for stage IV breast cancer and total of 8,279 patients (3,690 newly diagnosed
and 4,589 recurrent cases) for late-stage melanoma. Results are also available by
age and gender groups. CONCLUSIONS: Comparison of results using this epidemi-
ology tool with estimates from databases and chart review studies demonstrated
that our approach is reasonably accurate in its estimation. This approach could be
adopted for uncommon cancers or regions with scarce data.
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OBJECTIVES: Bladder cancer is a commonmalignancy with70,500 incident cases
per year in the US; 70% present as non-muscle invasive bladder cancer (NMIBC).
Perioperative instillation of chemotherapy after transurethral resection of the
bladder (TURBT) can reduce the risk of recurrence. Our objective was to estimate
the loss of quality-adjusted life years (QALY) due to unnecessary recurrences for
patients not receiving perioperative chemotherapy (PC). METHODS: A decision-
treemodel estimated the loss of QALYs following recurrence inNMIBC patients not
receiving PC. Therapy utilization rates were obtained from a chart review study of
1010 NMIBC patients treated by 259 US urologists. In this sample, 17% of patients
received PC after the initial TURBTand 27% received perioperative therapy after the
first recurrence. In addition, 48.6% received induction therapy with BCG (85%) or
mitomycin-C (MMC, 15%) after the first recurrence. The estimated 2-year recur-
rence rates in NMIBC patients were 53% with TURBT alone and 36% with TURBT
and PC. QALY estimates were obtained from literature with disutilities of0.10 for
each resection, 0.026 for BCG therapy, and an assumed 0.01 for MMC therapy.
RESULTS: According to estimates, 49,350 new cases of NMIBC are expected in the
US in 2010; 100% utilization of PC would result in avoidance of 6,962 bladder tumor
recurrences. Themodel estimates that 911 QALYs are lost over a 2-year time period
from preventable recurrences. This equates to 0.02 QALYs for all patients under-
going TURBT. An estimate of disutility at the first recurrence indicates a gain of
nearly 47 quality-adjusted days per avoidable recurrence and 8 days per new
NMIBC case if intravesical PCwas utilized.CONCLUSIONS:A substantial number of
QALYs are lost each year due to underuse of intravesical PC. Increased use of PC
could reduce the humanistic burden of unnecessary recurrences in NMIBC.
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OBJECTIVES: In 2010, an estimated 70,500 new cases of bladder cancer will be
diagnosed in the US; 70% will present as non-muscle invasive bladder cancer
(NMIBC). The instillation of intravesical chemotherapy after transurethral resec-
tion of bladder tumor (TURBT) can reduce the risk of tumor recurrence. The objec-
tive of this study is to estimate the economic consequences associated with un-
necessary recurrences in patients deprived of perioperative chemotherapy (PC).
METHODS: A decision-tree model estimated the economic consequences of recur-
rence in patients not receiving PC. Two sources were used to estimate rates for the
model because neither data source had both of the rates required; 1010 NMIBC
patient charts (from 259 US urologists) estimated therapy utilization, and recur-
rence rates were obtained from 502 patients enrolled in a trial by Tolley, et al.
randomizing patients to mitomycin C (MMC) versus no PC. Costs were estimated
using prevailing Medicare reimbursement rates for TURBT ($1,982), BCG induction
therapy ($201/instillation), MMC induction therapy ($252/instillation) and periop-
erative MMC ($166/instillation). RESULTS: Within the cohort, 17% of patients re-
ceived PC after the initial TURBT. The overall recurrence rate was 39%. At first
recurrence, 27% received PC and 48.6% received induction therapy with BCG (85%)
or MMC (15%). Data from the randomized trial indicate that at 2 years, 36% of
patients receiving PC recur compared with 53% receiving TURBT alone. Population
estimates predict 49,350 new cases of NMIBC in the US in 2010. The model demon-
strated prevention of 6962 bladder recurrenceswith perioperativeMMCafter initial
TURBT, with an estimated savings of $2608 per patient. This translates into aggre-
gate savings of $18.1 million to the US health care system over two years.
CONCLUSIONS: Greater use of PC after TURBT can reduce economic loss related to
preventable bladder tumor recurrences with substantial savings to the health care
system.
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OBJECTIVES:Although utility-based algorithms have been developed for the Func-
tional Assessment of Cancer Therapy (FACT), their properties are not well-known
compared to more widely used utility measures like the EQ-5D. The objective of
this study was to compare the properties and relationships between EQ-5D and
FACT-based health utility scores in cancer patients. METHODS: A retrospective
analysis was conducted on cross-sectional data collected from 534 cancer patients
who completed both FACT-G and EQ-5D. Properties of scores from 3 FACT-based
and 2 EQ-5D based algorithms were examined. Known groups comparisons were
based on physician and patient-rated ECOGperformance status. Relative efficiency
(RE) of the utility algorithms was examined using ratios of F-statistics. RESULTS:
Mean scores for the overall cohort were lowest using Kind and Macran’s FACT UK
societal (0.55, SD 0.09), followed by Dolan’s EQ-5D UK societal (0.72, SD 0.23),
Cheung et al.’s FACT mapped to EQ-5D (0.74, SD 0.11), Shaw et al.’s EQ-5D US
societal (0.79, SD 0.15), and highest using Dobrez et al’s FACT US patient algorithm
(0.83, SD 0.08). When stratified by ECOG status, the largest differences in mean
scores were generally observed for EQ-5D UK societal scores and smallest for the
FACT-based US patient scores; however, FACT UK societal scores had twice the
statistical efficiency of the other algorithms. CONCLUSIONS:We found important
differences in utilities scores estimated by each algorithm. The FACT-based algo-
rithms tended to underestimate the QALY benefit compared to the EQ-5D, and
appeared to driven by a more limited range of scale.
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COMPREHENSIVE REVIEW OF MANAGEMENT EFFICIENCY STRATEGIES AMONG
ONCOLOGY PRACTICES: EXISTING EVIDENCE AND OPPORTUNITIES FOR
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OBJECTIVES: Faced with decreasing reimbursement costs, greater patient vol-
umes, higher operating costs and pressure to adopt quality standards, community
oncology practices and infusion centers operate in an increasingly challenging
environment. This study sought to assess the practice efficiency techniques cur-
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